Mesoblast (MEOBF) Profit After Tax (2014 - 2023)
Mesoblast's (MEOBF) quarterly Profit After Tax came in at -$21.9 million in Q2 2023, down 2.16% year-over-year from -$22.4 million in Q2 2022, and down 17.84% quarter-over-quarter from -$18.6 million in Q1 2023.
Analysis
Mesoblast (MEOBF) Profit After Tax (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Profit After Tax across 10 years of filings, most recently posting -$21.9 million for Q2 2023.
- In Q2 2023, Profit After Tax fell 2.16% year-over-year to -$21.9 million; the TTM figure through Jun 2023 stood at -$82.0 million (up 10.36% YoY), while the FY2026 annual figure was -$57.5 million, up 43.71% from the prior year.
- Profit After Tax came in at -$21.9 million for Q2 2023 at Mesoblast, down from -$18.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $178.7 million in Q2 2021 to a low of -$57.6 million in Q1 2020.
- Average Profit After Tax over 5 years is -$13.8 million, with a median of -$24.5 million recorded in 2022.
- Year-over-year, Profit After Tax soared 55.32% in 2019 and tumbled 178.18% in 2020.
- Over 5 years, Profit After Tax stood at -$38.5 million in 2019, then jumped by 33.6% to -$25.5 million in 2020, then retreated by 1.57% to -$25.9 million in 2021, then rose by 5.62% to -$24.5 million in 2022, then climbed by 10.48% to -$21.9 million in 2023.
- Per Business Quant data, the three most recent Profit After Tax figures were -$21.9 million in Q2 2023, -$18.6 million in Q1 2023, and -$24.5 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 54.77 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | -93.84 Mn |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | -47.32 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 33.20 Mn |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | -81.06 Mn |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -123.80 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 20.07 Mn |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | -4.89 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 2.21 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -21.92 Mn |
| Mar 31, 2023 | -18.60 Mn |
| Dec 31, 2022 | -24.49 Mn |
| Sep 30, 2022 | -16.99 Mn |
| Jun 30, 2022 | -21.46 Mn |
| Mar 31, 2022 | -21.30 Mn |
| Dec 31, 2021 | -25.95 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | 178.71 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Mar 31, 2020 | -57.65 Mn |
| Dec 31, 2019 | -38.47 Mn |
| Sep 30, 2019 | -9.35 Mn |
| Jun 30, 2019 | -27.08 Mn |
| Mar 31, 2019 | -29.38 Mn |
| Dec 31, 2018 | -30.33 Mn |
| Sep 30, 2018 | -20.92 Mn |
| Jun 30, 2018 | -22.88 Mn |